Αποτελέσματα Αναζήτησης
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
Recent studies have shown that treatment of gynecological cancers during pregnancy is attainable, although oncological treatment needs to be individualized to ensure optimal maternal care and minimize potential effects to the fetus, while meeting the psychosocial needs of the family. Introduction.
25 Μαΐ 2020 · We wanted to compare the efficacy and safety of the anthracycline regimen EC-TH versus nonanthracycline regimen TCH in neoadjuvant setting for HER2-positive breast cancer.
14 Δεκ 2023 · SUMMARY AND RECOMMENDATIONS; INTRODUCTION; PATIENT ELIGIBILITY; TREATMENT OVERVIEW. General considerations; Patients who were treated with neoadjuvant therapy - Residual disease. T-DM1 - No residual disease. Trastuzumab, with or without pertuzumab; Patients who have not received neoadjuvant therapy; TRASTUZUMAB-BASED TREATMENT. Benefits
10 Αυγ 2023 · There are no human data regarding the safety of neurokinin-1 (NK-1) antagonists during pregnancy, but the first-generation agent aprepitant has been classified by the Food and Drug Administration as pregnancy class B under the prior system of pregnancy risk category classification.
20 Μαΐ 2024 · In 2020, ASCO published a guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer. 1 This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III ...
